Retrospective Study in a NSCLC M+ p (Ca_Pulmon)

AstraZeneca

Status: Completed

Conditions: EGFR Mutated Non-small Cell Lung Cancer Patients

Study type: Observational

Funder types: Industry

Identifiers

NCT01795352

NIS-OES-XXX-2012/1

Details and patient eligibility

About

This is a national, multicentre, non-interventional, retrospective study to be carried out in the oncology settings of approximately 15-20 Spanish hospitals.

At each participant hospital, all patients recently diagnosed with advanced EGFR mutated NSCLC (both newly or with recurrent disease , without previous treatment for metastatic disease) from April 2010 to December 2011 will be included as study population. Information about the follow-up of the patients during a minimum of 12 months after diagnosis will be collected.

Full description

Observational retrospective study to describe the management of advanced or metastatic EGFR mutated non-small cell lung cancer patients in Spain

Enrollment: 187 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed newly locally advanced or metastatic NSCLC (stage IIIB/IV)
• Confirmed EGFR mutation by a validated test
• Availability of medical record

Exclusion criteria

• Participating on a blinded randomized clinical trial at any time during the study period
• Pregnant women (due to they do not reflect daily clinical practice)